CITI/CALL/ELI LILLY & CO/320/0.1/16.01.25 | Market Closed - Deutsche Boerse AG 13:34:29 2024-07-05 EDT | ||
| 55.72 EUR | +2.75% |
|
| Current month | -0.73% | ||
| 1 month | +14.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 55.72 | +2.75% |
| 24-07-04 | 54.23 | -0.15% |
| 24-07-03 | 54.31 | -1.00% |
| 24-07-02 | 54.86 | -2.58% |
| 24-07-01 | 56.31 | +0.32% |
Delayed Quote Deutsche Boerse AG
Last update July 05, 2024 at 01:34 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Citi
|
| WKN | KH24SQ |
| ISIN | DE000KH24SQ7 |
| Date issued | 2023-02-01 |
| Strike | 320 $ |
| Maturity | 2025-01-16 (194 Days) |
| Parity | 10 : 1 |
| Emission price | 7 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 56.38 € |
|---|---|
| Lowest since issue | 5.19 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
914.6
USD
Average target price
870.3
USD
Spread / Average Target
-4.84%
- Stock Market
- Warrants
- Warrant
